0.397
price down icon0.75%   -0.003
 
loading
Schlusskurs vom Vortag:
$0.40
Offen:
$0.388
24-Stunden-Volumen:
129.40K
Relative Volume:
1.10
Marktkapitalisierung:
$11.12M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-58.52M
KGV:
-0.19
EPS:
-2.09
Netto-Cashflow:
$-45.03M
1W Leistung:
-25.19%
1M Leistung:
-45.54%
6M Leistung:
-69.69%
1J Leistung:
-83.46%
1-Tages-Spanne:
Value
$0.375
$0.4049
1-Wochen-Bereich:
Value
$0.3518
$0.5594
52-Wochen-Spanne:
Value
$0.3518
$2.49

Nextcure Inc Stock (NXTC) Company Profile

Name
Firmenname
Nextcure Inc
Name
Telefon
240-399-4900
Name
Adresse
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
Name
Mitarbeiter
43
Name
Twitter
@nextcureinc
Name
Nächster Verdiensttermin
2025-03-07
Name
Neueste SEC-Einreichungen
Name
NXTC's Discussions on Twitter

Vergleichen Sie NXTC mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
NXTC
Nextcure Inc
0.397 11.12M 0 -58.52M -45.03M -2.09
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 124.29B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 66.76B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 35.99B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.93B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.47B 3.81B -644.79M -669.77M -6.24

Nextcure Inc Stock (NXTC) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2022-11-04 Herabstufung Ladenburg Thalmann Buy → Neutral
2022-03-01 Eingeleitet Ladenburg Thalmann Buy
2021-03-05 Hochstufung Truist Hold → Buy
2021-01-15 Herabstufung BofA Securities Neutral → Underperform
2020-07-16 Hochstufung The Benchmark Company Hold → Buy
2020-07-13 Herabstufung ROTH Capital Buy → Neutral
2020-07-13 Herabstufung SunTrust Buy → Hold
2020-06-01 Herabstufung BofA/Merrill Buy → Neutral
2020-06-01 Herabstufung The Benchmark Company Buy → Hold
2020-05-26 Eingeleitet JMP Securities Mkt Outperform
2020-03-24 Eingeleitet The Benchmark Company Buy
2020-03-02 Eingeleitet ROTH Capital Buy
2020-01-13 Eingeleitet SunTrust Buy
2019-12-05 Eingeleitet Needham Buy
2019-11-26 Eingeleitet BTIG Research Buy
2019-07-09 Eingeleitet BofA/Merrill Buy
2019-06-03 Eingeleitet Morgan Stanley Overweight
2019-06-03 Eingeleitet Piper Jaffray Overweight
Alle ansehen

Nextcure Inc Aktie (NXTC) Neueste Nachrichten

pulisher
Apr 03, 2025

CLASS ACTION UPDATE for PLAN, NXTC and BTU: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire

Apr 03, 2025
pulisher
Apr 01, 2025

NextCure stock plunges to 52-week low, hits $0.46 - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

NextCure stock plunges to 52-week low, hits $0.46 By Investing.com - Investing.com Australia

Apr 01, 2025
pulisher
Mar 25, 2025

NextCure stock hits 52-week low at $0.55 amid market challenges By Investing.com - Investing.com South Africa

Mar 25, 2025
pulisher
Mar 25, 2025

NextCure stock hits 52-week low at $0.55 amid market challenges - Investing.com India

Mar 25, 2025
pulisher
Mar 19, 2025

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga

Mar 19, 2025
pulisher
Mar 18, 2025

H.C. Wainwright maintains Buy rating, $3 target on NextCure stock - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

H.C. Wainwright maintains Buy rating, $3 target on NextCure stock By Investing.com - Investing.com South Africa

Mar 18, 2025
pulisher
Mar 18, 2025

NextCure’s (NXTC) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Mar 18, 2025
pulisher
Mar 17, 2025

NextCure stock plunges to 52-week low at $0.66 amid market challenges - Investing.com Australia

Mar 17, 2025
pulisher
Mar 13, 2025

NextCure (NXTC) Projected to Post Quarterly Earnings on Thursday - Defense World

Mar 13, 2025
pulisher
Mar 10, 2025

2 Net Current Asset Value Stocks to Consider - GuruFocus.com

Mar 10, 2025
pulisher
Mar 08, 2025

Nextcure Faces Delisting Risk Amid Nasdaq Compliance Struggles - MSN

Mar 08, 2025
pulisher
Mar 07, 2025

NextCure Reports 2024 Financials and Strategic Progress - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

NextCure Provides Business Update and Reports Full Year 2024 Financial Results - The Manila Times

Mar 07, 2025
pulisher
Mar 06, 2025

NextCure, Inc. Completes First Cohort of Phase 1 Trial for LNCB74 and Plans for Backfill Cohorts - Nasdaq

Mar 06, 2025
pulisher
Mar 06, 2025

Can NextCure's $68M Cash Support Its Cancer Drug Development Through 2026? - StockTitan

Mar 06, 2025
pulisher
Feb 27, 2025

Korea Biotech Roundup: Orum, DongKook Price IPOs Below Band - insights.citeline.com

Feb 27, 2025
pulisher
Feb 27, 2025

NextCure stock plunges to 52-week low, hits $0.69 - MSN

Feb 27, 2025
pulisher
Feb 12, 2025

NextCure stock plunges to 52-week low, hits $0.69 By Investing.com - Investing.com Canada

Feb 12, 2025
pulisher
Feb 10, 2025

Ventia Strengthens Leadership with New Company Secretary Appointment - MSN

Feb 10, 2025
pulisher
Feb 10, 2025

Is NextCure (NASDAQ:NXTC) In A Good Position To Invest In Growth? - Yahoo Finance

Feb 10, 2025
pulisher
Feb 06, 2025

Eaton Vance Tax-Managed Diversified Equity Income Fund declares $0.0992 dividend - MSN

Feb 06, 2025
pulisher
Feb 04, 2025

NextCure Faces Potential Delisting from Nasdaq Global Select Market Due to Minimum Bid Requirement Non-Compliance - Defense World

Feb 04, 2025
pulisher
Jan 24, 2025

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Jan 24, 2025
pulisher
Jan 14, 2025

Geode Capital Management LLC Acquires 27,812 Shares of NextCure, Inc. (NASDAQ:NXTC) - Defense World

Jan 14, 2025
pulisher
Jan 14, 2025

Jane Street Group LLC Has $125,000 Holdings in Metalla Royalty & Streaming Ltd. (NYSEMKT:MTA) - Defense World

Jan 14, 2025
pulisher
Jan 13, 2025

NextCure Initiates Phase 1 Study for B7-H4 ADC Therapy to Treat Multiple Cancers_ - Defense World

Jan 13, 2025
pulisher
Jan 12, 2025

LigaChem Biosciences doses first patient in phase 1 trial of LNCB74 cancer drugCHOSUNBIZ - 조선비즈

Jan 12, 2025
pulisher
Jan 10, 2025

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 as Therapeutic for Treating Multiple Cancers - Marketscreener.com

Jan 10, 2025
pulisher
Jan 10, 2025

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers - The Manila Times

Jan 10, 2025
pulisher
Jan 10, 2025

NextCure Advances Cancer Treatment: First Patient Dosed in LNCB74 Phase 1 Trial - StockTitan

Jan 10, 2025
pulisher
Jan 07, 2025

Pre-market Movers: CDT, NARI, GDTC, NARI... - RTTNews

Jan 07, 2025
pulisher
Dec 25, 2024

NextCure stock hits 52-week low at $0.87 amid market challenges - Investing.com Australia

Dec 25, 2024
pulisher
Dec 25, 2024

NextCure stock hits 52-week low at $0.87 amid market challenges By Investing.com - Investing.com South Africa

Dec 25, 2024
pulisher
Dec 17, 2024

NextCure stock hits 52-week low at $0.99 amid market challenges By Investing.com - Investing.com South Africa

Dec 17, 2024
pulisher
Dec 16, 2024

NextCure stock hits 52-week low at $0.99 amid market challenges - Investing.com India

Dec 16, 2024
pulisher
Dec 12, 2024

The Buckle, Inc. Announces Dividend PayoutsKearney, NE — The Buckle, Inc. (NYSE: BKE) disclosed plans for upcoming shareholder dividend payments following the quarterly meeting of its Board of Directors on December 9, 2024. The company greenlighte - Defense World

Dec 12, 2024
pulisher
Dec 11, 2024

FDA clears IND for B7-H4-targeting ADC - BioWorld Online

Dec 11, 2024
pulisher
Dec 10, 2024

NextCure Announces Acceptance of IND Application for LNCB74 - The Manila Times

Dec 10, 2024
pulisher
Dec 10, 2024

NextCure, Inc. Announces Acceptance of IND Application for LNCB74 - Marketscreener.com

Dec 10, 2024
pulisher
Dec 10, 2024

NextCure's Cancer Drug LNCB74 Secures FDA IND Approval for Phase 1 Clinical Trials - StockTitan

Dec 10, 2024
pulisher
Dec 07, 2024

NextCure stock hits 52-week low at $1.00 amid market challenges - Investing.com Australia

Dec 07, 2024

Finanzdaten der Nextcure Inc-Aktie (NXTC)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
Kapitalisierung:     |  Volumen (24h):